From Principle to Practice: Bridging the Gap in Patient Profiling

PLoS ONE

Volumn 8, Issue 1, 2013, Pages

  Foley, Jonathan H ^a   Orfeo, Thomas ^a   Undas, Anetta ^b   McLean, Kelley C ^a   Bernstein, Ira M ^a   Rivard, Georges Etienne ^c   Mann, Kenneth G ^a   Everse, Stephen J ^a   Brummel Ziedins, Kathleen E ^a  

^a UNIVERSITY OF VERMONT   (United States)

^b JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^c UNIVERSITY OF MONTREAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 8; PROTEIN C; WARFARIN;

ADOLESCENT; ADULT; AGED; AGING; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING DISORDER; CLINICAL ARTICLE; DISEASE SEVERITY; DRUG EFFECT; DRUG HALF LIFE; DRUG RESPONSE; FEMALE; HEART ATRIUM FIBRILLATION; HEMOPHILIA A; HEMOSTASIS; HUMAN; MALE; PATIENT CODING; PREGNANCY OUTCOME; PROPHYLAXIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RISK ASSESSMENT; SIGNAL TRANSDUCTION; SIMULATION; THROMBIN TIME; THROMBOSIS; TREATMENT DURATION;

ADOLESCENT; ADULT; AGED; ANTICOAGULANTS; ATRIAL FIBRILLATION; BLOOD COAGULATION; COMPUTER SIMULATION; FACTOR VIII; FEMALE; HEMOPHILIA A; HUMANS; KINETICS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; PREGNANCY; PREMEDICATION; PROTEIN C; THROMBIN; WARFARIN; YOUNG ADULT;

EID: 84872871930     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0054728     Document Type: Article

References (49)

1. Nesheim ME, Taswell JB, Mann KG, (1979) The contribution of bovine Factor V and Factor Va to the activity of prothrombinase. J Biol Chem 254: 10952-10962.
2. Butenas S, Branda RF, van't Veer C, Cawthern KM, Mann KG, (2001) Platelets and phospholipids in tissue factor-initiated thrombin generation. Thromb Haemost 86: 660-667.
3. Kisiel W, Canfield WM, Ericsson LH, Davie EW, (1977) Anticoagulant properties of bovine plasma protein C following activation by thrombin. Biochemistry 16: 5824-5831.
4. Shatos MA, Orfeo T, Doherty JM, Penar PL, Collen D, et al. (1995) Alpha-thrombin stimulates urokinase production and DNA synthesis in cultured human cerebral microvascular endothelial cells. Arterioscler Thromb Vasc Biol 15: 903-911.
5. Levin EG, Marzec U, Anderson J, Harker LA, (1984) Thrombin stimulates tissue plasminogen activator release from cultured human endothelial cells. J Clin Invest 74: 1988-1995.
6. Belloni PN, Carney DH, Nicolson GL, (1992) Organ-derived microvessel endothelial cells exhibit differential responsiveness to thrombin and other growth factors. Microvasc Res 43: 20-45.
7. Herbert JM, Dupuy E, Laplace MC, Zini JM, Bar Shavit R, et al. (1994) Thrombin induces endothelial cell growth via both a proteolytic and a non-proteolytic pathway. Biochem J 303 (Pt 1):: 227-231.
8. Eikelboom JW, Hirsh J, (2006) Monitoring unfractionated heparin with the aPTT: time for a fresh look. Thromb Haemost 96: 547-552.
9. Quick AJ, Stanley-Brown M, Bancroft FW, (1935) A study of the coagulation defect in hemophilia and in jaundice. Am J Med Sci 190: 501-511.
10. Adcock DM, Duff S, (2000) Enhanced standardization of the International Normalized Ratio through the use of plasma calibrants: a concise review. Blood Coagul Fibrinolysis 11: 583-590.
11. Siegemund T, Petros S, Siegemund A, Scholz U, Engelmann L, (2003) Thrombin generation in severe haemophilia A and B: the endogenous thrombin potential in platelet-rich plasma. Thromb Haemost 90: 781-786.
12. Dargaud Y, Beguin S, Lienhart A, Al Dieri R, Trzeciak C, et al. (2005) Evaluation of thrombin generating capacity in plasma from patients with haemophilia A and B. Thromb Haemost 93: 475-480.
13. Hemker HC, Al Dieri R, De Smedt E, Beguin S, (2006) Thrombin generation, a function test of the haemostatic-thrombotic system. Thromb Haemost 96: 553-561.
14. Mann KG, Brummel K, Butenas S, (2003) What is all that thrombin for? J Thromb Haemost 1: 1504-1514.
15. Hron G, Kollars M, Binder BR, Eichinger S, Kyrle PA, (2006) Identification of patients at low risk for recurrent venous thromboembolism by measuring thrombin generation. JAMA 296: 397-402.
16. Nair SC, Dargaud Y, Chitlur M, Srivastava A, (2010) Tests of global haemostasis and their applications in bleeding disorders. Haemophilia 16 Suppl 5: 85-92.
17. Brummel-Ziedins KE, Pouliot RL, Mann KG, (2004) Thrombin generation: phenotypic quantitation. J Thromb Haemost 2: 281-288.
18. Brummel-Ziedins KE, Orfeo T, Rosendaal FR, Undas A, Rivard GE, et al. (2009) Empirical and theoretical phenotypic discrimination. J Thromb Haemost 7 Suppl 1: 181-186.
19. Danforth CM, Orfeo T, Everse SJ, Mann KG, Brummel-Ziedins KE, (2012) Defining the boundaries of normal thrombin generation: investigations into hemostasis. PLoS One 7: e30385.
20. Brodin E, Appelbom H, Osterud B, Hilden I, Petersen LC, et al. (2009) Regulation of thrombin generation by TFPI in plasma without and with heparin. Transl Res 153: 124-131.
21. van 't Veer C, Mann KG, (1997) Regulation of tissue factor initiated thrombin generation by the stoichiometric inhibitors tissue factor pathway inhibitor, antithrombin-III, and heparin cofactor-II. J Biol Chem 272: 4367-4377.
22. Allen GA, Wolberg AS, Oliver JA, Hoffman M, Roberts HR, et al. (2004) Impact of procoagulant concentration on rate, peak and total thrombin generation in a model system. J Thromb Haemost 2: 402-413.
23. Lutsey PL, Folsom AR, Heckbert SR, Cushman M, (2009) Peak thrombin generation and subsequent venous thromboembolism: the Longitudinal Investigation of Thromboembolism Etiology (LITE) study. J Thromb Haemost 7: 1639-1648.
24. Besser M, Baglin C, Luddington R, van Hylckama Vlieg A, Baglin T, (2008) High rate of unprovoked recurrent venous thrombosis is associated with high thrombin-generating potential in a prospective cohort study. J Thromb Haemost 6: 1720-1725.
25. Hockin MF, Jones KC, Everse SJ, Mann KG, (2002) A model for the stoichiometric regulation of blood coagulation. J Biol Chem 277: 18322-18333.
26. Butenas S, Orfeo T, Gissel MT, Brummel KE, Mann KG, (2004) The significance of circulating factor IXa in blood. J Biol Chem 279: 22875-22882.
27. Bravo MC, Orfeo T, Mann KG, Everse SJ, (2012) Modeling of human factor Va inactivation by activated protein C. BMC Syst Biol 6: 45.
28. Brummel-Ziedins KE, Orfeo T, Callas PW, Gissel M, Mann KG, et al. (2012) The prothrombotic phenotypes in familial protein C deficiency are differentiated by computational modeling of thrombin generation. PLoS One 7: e44378.
29. Busch C, Cancilla PA, DeBault LE, Goldsmith JC, Owen WG, (1982) Use of endothelium cultured on microcarriers as a model for the microcirculation. Lab Invest 47: 498-504.
30. Mann KG, (2011) Thrombin generation in hemorrhage control and vascular occlusion. Circulation 124: 225-235.
31. Brummel-Ziedins K, Vossen CY, Rosendaal FR, Umezaki K, Mann KG, (2005) The plasma hemostatic proteome: thrombin generation in healthy individuals. J Thromb Haemost 3: 1472-1481.
32. Hemker HC, Giesen P, AlDieri R, Regnault V, de Smed E, et al. (2002) The calibrated automated thrombogram (CAT): a universal routine test for hyper- and hypocoagulability. Pathophysiol Haemost Thromb 32: 249-253.
33. McLean KC, Bernstein IM, Brummel-Ziedins KE, (2012) Tissue factor-dependent thrombin generation across pregnancy. Am J Obstet Gynecol 207: 135 e131-136.
34. Brummel-Ziedins K, Undas A, Orfeo T, Gissel M, Butenas S, et al. (2008) Thrombin generation in acute coronary syndrome and stable coronary artery disease: dependence on plasma factor composition. J Thromb Haemost 6: 104-110.
35. Gissel M, Whelihan MF, Ferris LA, Mann KG, Rivard GE, et al. (2012) The influence of prophylactic factor VIII in severe haemophilia A. Haemophilia 18: 193-199.
36. Hale SA, Schonberg A, Badger GJ, Bernstein IM, (2009) Relationship between prepregnancy and early pregnancy uterine blood flow and resistance index. Reprod Sci 16: 1091-1096.
37. Hirsh J, Dalen J, Anderson DR, Poller L, Bussey H, et al. (2001) Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 119: 8S-21S.
38. Manco-Johnson M, (2007) Comparing prophylaxis with episodic treatment in haemophilia A: implications for clinical practice. Haemophilia 13 Suppl 2: 4-9.
39. Conway EM, Bauer KA, Barzegar S, Rosenberg RD, (1987) Suppression of hemostatic system activation by oral anticoagulants in the blood of patients with thrombotic diatheses. J Clin Invest 80: 1535-1544.
40. Dargaud Y, Desmurs-Clavel H, Marin S, Bordet JC, Poplavsky JL, et al. (2008) Comparison of the capacities of two prothrombin complex concentrates to restore thrombin generation in plasma from orally anticoagulated patients: an in vitro study. J Thromb Haemost 6: 962-968.
41. Orfeo T, Gissel M, Butenas S, Undas A, Brummel-Ziedins KE, et al. (2011) Anticoagulants and the propagation phase of thrombin generation. PLoS One 6: e27852.
42. Brummel-Ziedins K, Orfeo T, Jenny NS, Everse SJ, Mann KG (2009) Blood Coagulation and Fibrinolysis. In: Greer JP, Foerster J, Rodgers GM, Paraskevas F, Glader B et al., editors. Wintrobe's Clinical Hematology. Philadelphia: Wolters Kluwer, Lippincott Williams & Wilkins. pp. 528-619.
43. Khor B, Van Cott EM, (2010) Laboratory tests for protein C deficiency. Am J Hematol 85: 440-442.
44. Eichinger S, Weltermann A, Philipp K, Hafner E, Kaider A, et al. (1999) Prospective evaluation of hemostatic system activation and thrombin potential in healthy pregnant women with and without factor V Leiden. Thromb Haemost 82: 1232-1236.
45. Dargaud Y, Hierso S, Rugeri L, Battie C, Gaucherand P, et al. (2010) Endogenous thrombin potential, prothrombin fragment 1+2 and D-dimers during pregnancy. Thromb Haemost 103: 469-471.
46. Rosenkranz A, Hiden M, Leschnik B, Weiss EC, Schlembach D, et al. (2008) Calibrated automated thrombin generation in normal uncomplicated pregnancy. Thromb Haemost 99: 331-337.
47. Butenas S, Undas A, Gissel MT, Szuldrzynski K, Zmudka K, et al. (2008) Factor XIa and tissue factor activity in patients with coronary artery disease. Thromb Haemost 99: 142-149.
48. Wulfkuhle KC, Butenas S, Bernstein I, Brummel-Ziedins K, (2011) Tissue factor dependent and independent thrombin generation across pregnancy. J Thromb Haemost 9 Suppl 2: 431.
49. (2012) What happened to personalized medicine? Nat Biotechnol 30: 1.